[Table/Fig-1]:
Demographic data of 37 patients in the treatment group of locally advanced breast cancer
| Characteristics | Caf Regimen (n = 20) | PA Regimen (n = 17) | Overall (n = 37) |
|---|---|---|---|
| Median Age (Years) | 55 | 50 | 52.5 |
| Tumour Stage | No. of patients (%) | ||
| T3N0 | 1(5%) | 2(11.7%) | 3(8.1%) |
| T3N1 | 12(60%) | 11(64.7%) | 23(62.1%) |
| T4N1 | 6(30%) | 5(29%) | 11(29.7%0 |
| T4N2 | 0 | 1(5.8%) | 1(2.7%) |
| Pathology | |||
| Invasive Ductal | 20(100%) | 15(88.2%) | 35(94.5%) |
| Invasive Lobular | 0 | 1(5.8%) | 1(2.7%) |
| Others | 0 | 1(5.8%) | 1(2.7%) |
| Sbr Grade | |||
| I | 6(30%) | 4(23.5%) | 10(27%) |
| 2 | 13(65%) | 9(52.9%) | 22(29.4%) |
| 3 | 1(5%) | 1(5.8%) | 2(5.4%) |
| Clinical Response | |||
| Complete (CR) | 3(15%) | 4(23.5%) | 7(18.9%) |
| Partial (PR) | 11(55%) | 5(29.4%) | 16(43.2%) |
| No Response (NR) | 2(10%) | 4(23.5%) | 6(16.2%) |
| Progressive Disease (PD) | 4(20%) | 4(23.5%) | 8(21.6%) |
SBR:-Scarff-Bloom Richardson grade CAF:- Cyclophosphamide, Adriamycin, 5-fluoro uracil regimen PA:-Paclitaxel, Adriamycin regimen